RecruitingNot ApplicableNCT07317115

Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

Magnetic Compression Anastomosis in Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes (MAGvMED Study)

Sponsor

GT Metabolic Solutions, Inc.

Enrollment

20 participants

Start Date

Mar 1, 2026

Study Type

INTERVENTIONAL

Conditions

Obesity (Disorder)

Summary

Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two treatments for adults with obesity and type 2 diabetes: a surgical procedure (a side-to-side connection between the small intestine and the duodenum) versus a weekly semaglutide injection (a medication that reduces blood sugar and body weight). **You may be eligible if...** - You are an adult with a BMI between 30 and 40 - You have type 2 diabetes (HbA1c of 6.5% or higher) - Your doctor agrees you are a suitable candidate for both the surgery and the medication - You agree not to take any other GLP-1 medications or have additional weight-loss surgeries during the study **You may NOT be eligible if...** - You have already had weight-loss surgery in the past 12 months (e.g., gastric sleeve or gastric band) - You have taken semaglutide or any GLP-1 medication in the past 12 months - You are pregnant, breastfeeding, or planning to become pregnant during the study - You have a medical condition that prevents you from safely having either the surgery or the medication Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMagnet System

Magnet System for side-to-side magnetic compression anastomosis in a duodeno-ileostomy bipartition

DRUGSemaglutide

Semaglutide (up to 2.4mg subcutaneous (SQ) injection weekly or dose tolerated according to side effects); a glucagon-like peptide-1 receptor agonist (GLP-1RA)